A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2015
Price : $35 *
At a glance
- Drugs Epratuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors UCB Pharma Inc
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2013 Planned end date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 08 Apr 2013 New trial record